Outlook Therapeutics Inc News - OTLKW

Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress

ISELIN, N.J., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER...

Securities Registration: Employee Benefit Plan (s-8)

As filed with the Securities and Exchange Commission on February 14, 2022 Registration No...

Quarterly Report (10-q)

P1Y0000002242606020001649989--09-302022Q1false176461628004500000.58000002000000001649989us-gaap:MeasurementInputSharePriceMember2021-12-310...

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update

Outlook Therapeutics remains on track to submit new U.S. FDA Biologics License Application (BLA) for first...

Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

ISELIN, N.J., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

Joel Prieve brings nearly 20 years of commercial operations expertise and proven track record in sales and...

Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

ISELIN, N.J., Feb. 02, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Amended Statement of Beneficial Ownership (sc 13d/a)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE...

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Outlook Therapeutics advancing first ever ophthalmic formulation of bevacizumab towards new U.S. FDA Biologics...

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

ISELIN, N.J., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

ISELIN, N.J., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a...

Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW)

Professional-Grade Tools, for Individual Investors.

OTLKW News

Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress

Statement of Changes in Beneficial Ownership (4)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

Securities Registration: Employee Benefit Plan (s-8)

Quarterly Report (10-q)

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update

Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Statement of Changes in Beneficial Ownership (4)

OTLKW Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Outlook Therapeutics Inc (OTLKW) News

Outlook Therapeutics Inc (OTLKW)

Professional-Grade Tools, for Individual Investors.

OTLKW News

Outlook Therapeutics to Present at the RANZCO 52nd Annual Scientific Congress

Statement of Changes in Beneficial Ownership (4)

Notification Filed by National Security Exchange to Report the Removal From Listing and Registration of Matured, Redeemed or Retired Securities Initial Filing Amendments (25-nse)

Securities Registration: Employee Benefit Plan (s-8)

Quarterly Report (10-q)

Outlook Therapeutics Reports Financial Results for First Quarter Fiscal Year 2022 and Provides Corporate Update

Outlook Therapeutics to Present at the 11th Annual SVB Leerink Global Healthcare Conference

Outlook Therapeutics Expands Commercial Team with Appointment of Senior Vice President of Commercial Operations

Outlook Therapeutics to Present at the Fourth Annual Telluride Retina Film Festival

Statement of Changes in Beneficial Ownership (4)

Amended Statement of Beneficial Ownership (sc 13d/a)

Outlook Therapeutics Provides a Corporate Update and Business Outlook

Outlook Therapeutics to Present at the Virtual Investor 2022 Top Picks Conference

Outlook Therapeutics to Present at the H.C. Wainwright BioConnect Conference

Statement of Changes in Beneficial Ownership (4)

OTLKW Discussion

Your Recent History